... response. At least one pharmaceuticalcompany is applying the IFN signature as a rapid indicator ofclinical response in early phase I/II trials targeting IFNα by a monoclonal antibody [28]. Notably, ... B-cell activating factor in Chinese systemiclupus erythematosus patients. J Clin Lab Anal 2007, 21:183-187.41. Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa ... L, AllantazF, Mejias A, Ardura M, Kaizer E, Monnet L, Allman W, Randall H,Johnson D, Lanier A, Punaro M, Wittkowski KM, White P, Fay J,Klintmalm G, Ramilo O, Palucka AK, Banchereau J, Pascual...